Could a higher dose of rifampicin beat TB faster?

NCT ID NCT06057519

Recruiting now Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a higher dose of the antibiotic rifampicin (1800 mg daily) is safe and works better than the standard dose for adults with pulmonary tuberculosis. About 164 participants will be randomly assigned to either the optimized or standard dose. Researchers will monitor liver toxicity, side effects, and cure rates to see if the higher dose improves outcomes without increasing harm.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rifampicin
What this could lead to: If successful, this could lead to a more effective and still safe dosing regimen for tuberculosis, potentially improving cure rates.
What could go wrong: This is a phase 3 trial, but the higher dose may cause more liver toxicity, and results may not apply to all TB patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS, PULMONARY

Contacts and locations

Locations

ASL Città di Torino
RECRUITING

Turin, Italy
Radboud University Medical Centre
RECRUITING

Nijmegen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.